NCT00181688

Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer

A Phase II Study of ZD1839 (Iressa) Plus Anastrozole (Arimidex) in Patients With Relapsed Ovarian Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 35 (planned)
• Sponsor: Massachusetts General Hospital · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to determine the effects (good and bad) Iressa plus anastrozole has on patients with relapsed ovarian cancer.

Detailed description

* Patients will receive Iressa and anastrozole orally once daily until treatment is ended. Treatment will end if any of the following occur: Unacceptable adverse effects; bowel obstruction; initiation of systemic chemotherapy; development of new ascites or pleural effusions, development of co-morbid disease or disease progression. * Patients will be given a drug log in which to record the date and time they take their pills, as well as any symptoms and concomitant medications. * Patients will be seen monthly for the following tests and procedures; a physical examination and repeat blood work. Patients who remain free of clinical symptoms should have repeat abdominal/pelvic CT scans and chest x-rays on an every 3 month basis.

Conditions

• Ovarian Cancer
• Peritoneal Carcinoma
• Tubal Carcinoma

Interventions

Type	Name	Description
DRUG	Iressa (ZD1839)
DRUG	Arimidex (Anastrozole)

Timeline

• Start date: 2003-10-01
• Primary completion: 2006-03-01
• Completion: 2006-03-01
• First posted: 2005-09-16
• Last updated: 2012-12-05

Locations

2 sites across 1 country: United States